KHAN Technology Transfer Fund
VC Fund
Dortmund, Germany
KHAN Technology Transfer Fund is a VC fund in Dortmund focused on Biotechnology and Medical. KHAN Technology Transfer Fund operates as an investment firm.
- Total investments:
- 15
- Last investment:
- Lead investor:
- 53%
Last updated:
For AI agents: llms.txt
Industries KHAN Technology Transfer Fund invests in
Stages KHAN Technology Transfer Fund invests in
Countries KHAN Technology Transfer Fund invests in
Round sizes
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Round size
- Seed
- $259k–$10M
- Series A
- $5.6M–$10M
Investment Focus
Industry
- Biotechnology 6 (40%)
- Medical 4 (27%)
- Biopharma 2 (13%)
- Pharmaceutical 2 (13%)
- Genetics 1 (7%)
Stage
- Seed 7 (47%)
- Pre-Seed 1 (7%)
- Series A 1 (7%)
- Venture - Series Unknown 1 (7%)
Country
- Germany 3 (20%)
- Austria 1 (7%)
- Belgium 1 (7%)
- Luxembourg 1 (7%)
- Czech Republic 1 (7%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
Michael Hamacher
Managing Partner and CFO
|
Managing Partner and CFO | Total investments: 1 | Find email |
Investments
| Company | Description | Round | Links |
|---|---|---|---|
| Revier Therapeutics is a biotechnology company focused on developing innovative solutions to improve human health and treat diseases. | $7M / Seed / Aug 25, 2026 | ||
| iDEL Therapeutics is advancing a new class of cancer medicines by delivering therapeutic payloads directly into the cytosol of tumor cells through a unique, pan-cancer uptake mechanism. | $10.4M / Seed / Mar 17, 2026 | ||
| KyDo Therapeutics is a biotechnology company that develops novel covalent-allosteric small molecule inhibitors. | $5.3M / Seed / Sep 16, 2025 | ||
| Casinvent Pharma develops new therapeutic options for the treatment of selected malignancies. | Venture - Series Unknown / Jul 02, 2025 | ||
| RIANA Therapeutics is a spin-off from the University of Veterinary Medicine Vienna, developing first-in-class small-molecule inhibitors targeting oncogenic STAT5 signaling in Acute Myeloid Leukemia (AML). Our proprietary phenotypic screening platform enables identification of compounds selectively disrupting STAT5 oligomerization — a driver of AMLresistance — while preserving normal cell function. Having completed hit validation, RIANA is raising a seed round to advance to lead identification. Backed by non-dilutive funding. | $258.8K / Seed / Jan 01, 2025 | ||
| Casinvent Pharma develops new therapeutic options for the treatment of selected malignancies. | $1.7M / Seed / Jan 30, 2024 | ||
| OrganoTherapeutics use cutting-edge human-specific mini-brains for the discovery and development of effective drug candidates targeting Parkinson’s disease. We screen new molecules on our proprietary human-specific minibrains which represent a model mimicking faithfully the human Parkinson’s disease pathology. OrganoTherapeutics aims at developingnew drug candidates against Parkinson’s disease which are tested in state-of-the art 3D patient models. OrganoTherapeutics has developed first own proprietary drug candidates and has access to attractive libraries for further screening. | Seed / Jul 26, 2023 | ||
| RIANA Therapeutics is a spin-off from the University of Veterinary Medicine Vienna, developing first-in-class small-molecule inhibitors targeting oncogenic STAT5 signaling in Acute Myeloid Leukemia (AML). Our proprietary phenotypic screening platform enables identification of compounds selectively disrupting STAT5 oligomerization — a driver of AMLresistance — while preserving normal cell function. Having completed hit validation, RIANA is raising a seed round to advance to lead identification. Backed by non-dilutive funding. | $857.2K / Pre-Seed / Feb 08, 2023 | ||
| Nodus Oncology Developing the DDR targeting therapies. | $2.9M / Seed / Feb 07, 2023 | ||
| Casinvent Pharma develops new therapeutic options for the treatment of selected malignancies. | $1.3M / Seed / Sep 13, 2022 | ||
| See all 15 investments → | |||
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar industry
Similar country
Featured in Investor Lists
Recommended lists
FAQ
What does KHAN Technology Transfer Fund invest in?
KHAN Technology Transfer Fund invests primarily in Biotechnology, Medical and Biopharma startups, most often at Seed and Pre-Seed stage. Most of the 15 investments tracked by Shizune back companies in Germany. The Investment Focus section breaks down every industry, stage and country in the portfolio.
What is KHAN Technology Transfer Fund's check size?
KHAN Technology Transfer Fund typically joins rounds of $259k–$10M at Seed and $5.6M–$10M at Series A. These ranges are 10th–90th percentile round sizes calculated from confirmed public funding rounds, so they are a realistic guide to the rounds KHAN Technology Transfer Fund participates in.
How do I contact KHAN Technology Transfer Fund?
Public channels for KHAN Technology Transfer Fund include LinkedIn and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at KHAN Technology Transfer Fund?
The team at KHAN Technology Transfer Fund includes Michael Hamacher (Managing Partner and CFO). The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Oct 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
